StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Net Sales in Rest of World by Quarter

Net Sales in Rest of World ($M)

QuarterlyAnnual

Novartis Net Sales in Rest of World: $103M in Q3 2026, down 27.5% from a year earlier. That is the lowest of the 32 quarters on record here.

Latest, Q3 2026
103
Period ended Sep 30, 2026
Change on a year earlier
-27.5%
142 in Q3 2025
History
32 quarters
Since Q4 2018
Sources
32
Documents cited below

Where the Q3 2026 figure comes from

“|| Tasigna | Established brands | Chronic myeloid leukemia (CML) | 38 | – 52 | 103 | – 27 | – 29 | 141 | – 36 | – 37”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F (Top 20 Brands US / Rest of World).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNet Sales in Rest of World ($M)Year on yearSource
Q3 2026Sep 30, 2026103-27.5%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 2026112-32.1%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 2026127-29.4%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 2025131-32.1%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 2025142-26.4%Novartis Form 6-K (0001114448-25-000003) ↗
Q2 2025Jun 30, 2025165-23.6%Novartis Form 6-K (0001370368-25-000012) ↗
Q1 2025Mar 31, 2025180-18.6%Novartis Form 6-K (0001370368-25-000010) ↗
Q4 2024Dec 31, 2024193-14.6%Novartis Form 6-K (0001370368-25-000007) ↗
Q3 2024Sep 30, 2024193-20.6%Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2024Jun 30, 2024216-11.5%Novartis Form 6-K (0001370368-24-000019) ↗
Q1 2024Mar 31, 2024221-12.0%Novartis Form 6-K (0001370368-24-000017) ↗
Q4 2023Dec 31, 2023226-10.3%Novartis Form 6-K (0001370368-24-000007) ↗
Q3 2023Sep 30, 2023243-4.7%Novartis Form 6-K (0001370368-23-000068) ↗
Q2 2023Jun 30, 2023244-12.9%Novartis Form 6-K (0001370368-23-000059) ↗
Q1 2023Mar 31, 2023251-3.1%Novartis Form 6-K (0001370368-23-000046) ↗
Q4 2022Dec 31, 2022252-9.4%Novartis Form 6-K (0001370368-23-000008) ↗

Breakdown

What makes up net Sales in Rest of World

Cite this data

StockData. (2026). Novartis Net Sales in Rest of World ($M), quarterly Q4 2018–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-tasigna-row-sales

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.